Drug Sensitivity Testing for Cancer Therapy, Technique Analysis and Trends.

The techniques and qualities of drug sensitivity testing (DST) for anticancer treatment have grown rapidly in the past two decades worldwide. Much of DST progress came from advanced systems of technical versatility (faster, highly-throughput, highly-sensitive, and smaller in tumor quantity). As the earliest drug selective system, biomedical knowledge and technical advances for DST are mutually supported. More importantly, many pharmacological controversies are resolved by these technical advances. With this technical stride, the clinical landscape of DST entered into a new phase (>500 samples per testing and extremely low quantity of tumor cells). As a forerunner of the drug selection system, DST awaits a new version that can adapt to complicated therapeutic situations and diverse tumor categories in the clinic. By upholding this goal of pathogenic and therapeutic diversity, DST could eventually cure more cancer patients by establishing high-quality drug selection systems. To smoothen DST development, there is a need to increase the understanding of cancer biology, pathology and pharmacology (cancer heterogeneity, plasticity, metastasis and drug resistance) with well-informative parameters before chemotherapy. In this article, medicinal and technical insights into DST are especially highlighted.

HIV/AIDS Curability Study, Different Approaches and Drug Combination.

AIM: HIV infection is currently an incurable disease characterized by life-long drug utility. Its incurable causality and mechanism are still unknown to us. METHODS: To overcome this therapeutic setback, some breakthroughs should be made by utilizing different approaches. How to plan some experimental and clinical novelty for HIV curability is a modern challenge. In this article, new ideas and approaches for global HIV/AIDS therapeutic strategies are proposed and represented by scientific insights. RESULTS: Pharmaceutical characteristics, herbal medicine, novel drug targets, cutting-edge biotherapy, drug combination, animal modalities, and immune-stimuli for HIV latency, as well as clearance, are highlighted. DISCUSSION: To elucidate our understanding of curative treatment for HIV/AIDS, many new pathological discoveries, expansion, technical advances, and potential drug targets are constructed. After the discovery of novel pathogenesis and therapeutic evolution, HIV/AIDS therapeutic curability may become achievable and a reality. CONCLUSION: Transformation from animal model investigation to widespread therapies for larger volume of human population is a necessity in modern medicine. In this infectious treatment scenario, major breakthroughs in medicine and drug development are anticipated.

Covid-19 Study, Diagnostic and Therapeutic Transition.

INTRODUCTION: The outbreak of coronavirus (severe acute respiratory syndrome coronavirus2, COVID-19, SARS-Co-2) in Wuhan, China occurred three years ago. However, the healthcare state and legislature for Covid-19 varied greatly worldwide. AIMS: After three years, the social life of most countries worldwide is gradually back to normal. Diagnosis and therapeutics worldwide are formalized now. Improvement of the knowledge about this devastating disease will shed new light on its management and spawn the development of new counter measures. Due to the differences in socioeconomic conditions and policies worldwide, the diagnostic and therapeutic transition should be established. METHODS: The schedules and techniques of vaccines, drugs, or other therapeutic strategies could be formalized in the future. The origin and hidden nature of Covid-19 biology (relationship between viral strain and drug targeting) should be further investigated. Knowledge and opinion breakthroughs may significantly heighten the quality of preventive and therapeutic strategies against Covid-19. RESULTS: To further stabilize the global situation, the issues of viral spread and induced mortality should be emphasized. Existing animal models, pathophysiological knowledge, and therapeutics for different infected patients played vital roles. The diagnostic widening, variants of COVID, and therapeutic selection worldwide totally solve the complex outcomes and promote the curability for infected patients. DISCUSSION: Different diagnostic platforms can reach different therapeutic selections, responses, and benefits in the clinic. It will provide advanced diagnostic dimensions, therapeutic paradigms, and drug selection strategies for the purpose of the greatest benefiting and recoveries of Covid-19 patients. CONCLUSION: To speed up the global fight against Covid-19, biomedical knowledge, prophylactic vaccines, and therapeutic paradigms should be updated in dynamic states.

Drug Sensitivity Testing for Cancer Therapy, Key Areas.

AIMS: Cancer is a high-mortality disease (9.6 million deaths in 2018 worldwide). Given various anticancer drugs, drug selection plays a key role in patient survival in clinical trials. METHODS: Drug Sensitivity Testing (DST), one of the leading drug selective systems, was widely practiced for therapeutic promotion in the clinic. Notably, DSTs assist in drug selection that benefits drug responses against cancer from 20-22% to 30-35% over the past two decades. The relationship between drug resistance in vitro and drug treatment benefits was associated with different tumor origins and subtypes. Medical theory and underlying DST mechanisms remain poorly understood until now. The study of the clinical scenario, sustainability and financial support for mechanism and technical promotions is indispensable. RESULTS: Despite the great technical advance, therapeutic prediction and drug selection by DST needs to be miniature, versatility and cost-effective in the clinic. Multi-parameters and automation of DST should be a future trend. Advanced biomedical knowledge and clinical approaches to translating oncologic profiles into drug selection were the main focuses of DST developments. With a great technical stride, the clinical architecture of the DST platform was entering higher levels (drug response testing at any stage of cancer patients and miniaturization of tumor samples). DISCUSSION: The cancer biology and pharmacology for drug selection mutually benefit the clinic. New proposals to reveal more therapeutic information and drug response prediction at genetic, molecular and omics levels should be estimated overall. CONCLUSION: By upholding this goal of non-invasive, versatility and automation, DST could save the life of several thousand annually worldwide. In this article, new insights into DST novelty and development are highlighted.

Ebola Therapeutic Study and Future Directions.

The constant Ebola epidemic outbreaks in Africa arisen in waves of panic worldwide. There is a high mortality rate (30-70%) among the Ebola-infected people in virus- stricken areas. Despite these horrors, the medical capabilities against this deadly viral disease were provided by limited therapeutic agents/options. As a result, several patented agents, biotherapies or prophylactic/therapeutic vaccines need to be reviving into the global markets-including patents of small molecular chemicals, short sequences or oligomers of DNA/RNA, linkages of chemicals with bio-molecules, herbal medicine and so on. In addition, the possible mechanisms of action of these therapeutic options are underway. To promote Ebola biomedical study, the multiple characters of Ebola infections-its origin, pathologic progress, genomic changes, therapeutic context and economic considerations are outlined in this review. Finally, a great difference can be expected after these types of efforts.

RETRACTED: Human Suicide, Modern Diagnosis Assistance and Magic Bullet Discovery

The article entitled "Human Suicide, Modern Diagnosis Assistance and Magic Bullet Discovery", by Da-Yong Lu, Peng- Peng Zhu, Hong-Ying Wu, Nagendra Sastry Yarla, Bin Xu, Jian Ding, Ajit Varki and Ting-Ren Lu, has been retracted on the request of the co-authors, Dr. Ajit Varki, Dr. Nagendra Sastry Yarla and Dr. Jian Ding available at: Cent Nerv Syst Agents Med Chem 2019; 19(1): 15-23. http://www.eurekaselect.com/169003/article.The Corresponding Author Dr. Da-Yong Lu has included the names of the co-authors, Dr. Ajit Varki, Dr. Nagendra Sastry Yarla and Dr. Jian Ding without their consent and the manuscript has been published in the journal, Central Nervous System Agents in Medicinal Chemistry (CNSAMC). Kindly see Bentham Science Policy on Article retraction at the link given below:(https://benthamscience.com/journals/central-nervous-system-agents-in-medicinal-chemistry/author-guidelines/)Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such, this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.

HAART in HIV/AIDS Treatments: Future Trends.

AIDS (acquired immune deficient syndrome) is a deadly human viral infectious disease caused by HIV (human immune-deficient virus) infection. Almost every AIDS patient losses his/her life before mid 1990s. AIDS was once the 1st disease killer in US (1993). After one decade hard work, antiviral drug cocktails-high active anti-retroviral therapy (HAART) have been invented for almost all HIV infection treatments. Due to the invention of HAART, 80-90% HIV/AIDS patients still effectively response to HAART for deadly AIDS episode controls and life saving. Yet, this type of HIV therapeutics is incurable. HIV/AIDS patients need to take HAART medications regularly and even life-long. To counteract this therapeutic drawback, more revolutionary efforts (different angles of therapeutic modes/attempts) are urgently needed. In this article, the major progresses and drawbacks of HIV/AIDS chemotherapy (HAART) to HIV/AIDS patients have been discussed. Future trends (updating pathogenesis study, next generations of drug developments, new drug target discovery, different scientific disciplinary and so on) are highlighted.

Human Suicide Risk and Treatment Study.

INTRODUCTION: Suicide is still a major event of human mortality worldwide. Yet human suicide prediction, prevention and therapeutic systems at this moment are generally ineffective in the clinic. No diagnostic system is reliable for significantly suicidal prevention and mortality reduction. As a result, human suicide etiopathologic investigation (especially at genetic/molecular levels in the clinical settings) is quite necessary. In order to boost human suicide researches, emerging human suicide diagnostic/treatment study will be transformed from clinical symptom observations into new generations of candidate drug targets and therapeutics. To achieve this goal, associations between suicidal etiopathologic identification, genetic/bioinformatics-based diagnostics and putative drug targets must be exploited than ever before. After all, the interaction and relationships between environmental/ genetic/molecular clues and overall patient's risk prediction (environmental influences and different therapeutic targets/types) should be found out. CONCLUSION: In the future, effective clinical suicide prediction, prevention and therapeutic systems can be established via scientific expeditions and causality discovery.

HIV/AIDS Curable Study: New Forms of Therapeutic Trinity.

BACKGROUND AND AIMS: AIDS (acquired immune deficient syndrome), a deadly human infectious disease is caused by HIV (human immunodeficiency viruses) infection. Patient's mortality was eventually reduced to one-fourth by combined chemotherapy (usually 3 chemical drugs simultaneously) than earlier HIV/AIDS treatments (single drug or vaccine) in the clinic. RESULTS: Combined treatments against HIV/AIDS are still incurable for all patients despite a high rate of patient's survival. Basic viral pathological study and advancing drug development systems for curable medications are indispensable nowadays and in the future. CONCLUSION: Up to date, therapeutic trinity (combined therapy) against HIV/AIDS is generally among chemical drugs. In this article, several forms of other therapeutic attempts for effectively curing efforts against HIV/AIDS are proposed-including the development of next generation therapeutic HIV vaccines and schedules, new categories of bio-therapy, different pathways of immune-modulation, herbal medicines in general (allopathic, Ayurveda and traditional Chinese medicines), high quality of physical exercises, and especially therapeutic combinations guided by latest medical discovery and principles (new forms of therapeutic trinity against HIV-induced pathogenesis and human mortality).

Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics.

BACKGROUND: Last two to three decades, this world witnesses a rapid progress of biomarkers and bioinformatics technologies. Cancer bioinformatics is one of such important omics branches for experimental/clinical studies and applications. METHODS: Same as other biological techniques or systems, bioinformatics techniques will be widely used. But they are presently not omni-potent. Despite great popularity and improvements, cancer bioinformatics has its own limitations and shortcomings at this stage of technical advancements. RESULTS: This article will offer a panorama of bioinformatics in cancer researches and clinical therapeutic applications-possible advantages and limitations relating to cancer therapeutics. A lot of beneficial capabilities and outcomes have been described. As a result, a successful new era for cancer bioinformatics is waiting for us if we can adhere on scientific studies of cancer bioinformatics in malignant- origin mining, medical verifications and clinical diagnostic applications. CONCLUSION: Cancer bioinformatics gave a great significance in disease diagnosis and therapeutic predictions. Many creative ideas and future perspectives are highlighted.

Anticancer Drug Combinations, How Far We can Go Through?

Many clinical cancer therapies are less effective by using one anticancer drug only due to refractory properties of cancer pathogenesis and drug resistance property in advanced cancer patients. A general consensus among clinicians is that anticancer drug cocktail might better control cancer progresses and metastasis than single drug therapeutics in clinical trials. Despite great popularity, the anticancer drug combination dogma has not been established. The complexity of drug combination dogma discovery is more than we can expect now. This article speculates possible routes we can undertake in this matter. The background knowledge of drug combination therapy presently practiced and possible future landscapes and drawbacks of cancer drug combinative therapies are highlighted.

Drug Combination in Clinical Cancer Treatments.

AIM: The modality of anticancer drug combinations needs to be renovated from empirical into technical-supportive systems. METHODS: To challenge past therapeutic routines, the new landscape may be established. Among the different areas of anticancer drug combination study, research in the fields of medical study is the most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/ molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data analysis, therapeutic toxicity monitor, personalized cancer medicine and so on. DISCUSSION: This article addresses these types of cancer therapeutic management systems for clinical anticancer drug combination utilities. CONCLUSION: Future cancer drug combinational studies and clinical optimums must be implemented.

The Suicidal Risks and Treatments, Seek Medications from Multi-disciplinary.

Suicide events and episodes are serious human psychiatric disorders affected by a great number of different environmental/economic factors, early trauma/abuse, human bad living habits, human genomic properties and drug intervention decisions. In order to improve antidepressant therapeutics in clinics, the relationships between efficacy and toxicities of antidepressants have to be considered fundamentally. Since the occurrences and risks of suicidal events or episodes come from interplay between insiders (chemical/genomic/bioinformatics factors) and outsiders (economic/social/ previous trauma conditions and so on), new perspectives and scientific studies must be implemented for revealing these interrelated factors step-by-step and updating therapeutics in human beings. New paradigms and clinical strategies -joint-expert groups and clinical practices (a psychiatrist with other field specialists) should be established for individual patients in future. Thus can some improvements in clinical trials be achieved in a long run?

HIV Vaccination, is Breakthrough Underway?

After long defeats-almost no marked breakthrough in HIV vaccination campaign has been observed during the past two decades, and we still have not lost our faiths for the development of highly effective and low risk HIV vaccines. Many effective vaccines have been discovered and will certainly enter into the markets within the next 5 to 10 years. In order to promote HIV vaccine developments and clinical HIV therapeutic improvements, this perspective addresses the good and bad sides of currently available HIV vaccines, discusses many subjects of medical significance and finally provides up-to-date information in the field of HIV studies, in particular regarding vaccine developments and HIV pathogenesis.

HIV Vaccine for Prevention and Cure, A Mission Possible.

HIV/AIDS was once a highly deadly infective disease that killed the global people of a million annually two decades ago. While we are enjoying the HIV therapeutic advances (mostly important from HAART invention), one obvious drawback is still unresolved-unable to clearance all HIV from infected human bodies. As a result, a series of different therapeutic attempts have been proposed based on present knowledge of different features of HIV-induced pathogenesis and human mortalities. Facing this shortcoming, innovative designs and update of HIV vaccines and other types of HIV therapeutic inventions can be a final solution for completely HIV clearance and infection managements in human beings. Owing to these scientific and medical significances, several experimental and clinical attempts have to be made. Among these attempts, part of them (updating HIV vaccine developments and clinical routines) are quite promising and noteworthy. In this article, we offer the general information of this attempt and discuss it separately, especially on the respects of HIV vaccine strategic innovations.

Pharmacogenetics of cancer therapy: breakthroughs from beyond?

'Pharmacogenetics or Pharmacogenomics' (PG) is one of the most practiced cancer therapeutic strategies, tailored for individualized patients. Despite its popularity and rapid advancements in the field, many obstacles for cancer therapy PG still need to be overcome. By borrowing scientific systems from other disciplines such as cancer diagnosis, and therapeutic information from the diversity of tumor origins, categories and stages, cancer therapy PG may hopefully be improved. Furthermore, to quickly acquire genetic and pathologic information and seek therapeutic interventions, possible breakthroughs may come from beyond - changing the cancer therapeutic landscapes. The next generations of PG protocols and hospital routines for searching deadly cancer pathogenic pathways versus drug-targeting predictions are of great clinical significance for the future. Yet, progress of cancer therapy PG is entering into a bottleneck stage owing to simple model of relevant techniques and routines. Promoting or even innovating present PG modular is very necessary. This perspective highlights this issue by introducing new initiatives and ideas.

The Efficacies and Toxicities of Antidepressant Drugs in Clinics, Building the Relationship between Chemo-Genetics and Socio-Environments.

Antidepressants generally relief human depressive symptoms and help depressed people. Nevertheless, some undesired clinical events, such as suicide have been emerging more recently. In order to improve and promote antidepressant utilizations in clinics, new researches are focusing on reevaluation of the relationship between efficacy and toxicities of antidepressants in China and US. These researches speed up quickly. Many creative ideas and discoveries have been made, including predictions of the efficacies and toxicities of antidepressants under the same evaluating systems (pharmacogenetics and bioinformatics), genome-wide associate study (GWAS) of the relationship between individual genetic factors and therapeutic outcomes of different types of antidepressants and socio-environmental factors. Hopefully, therapeutic efficacies and outcomes by different types of antidepressant treatments for patients can be improved in clinical trials in the near future.

New Perspectives of HIV/AIDS Therapy Study.

HIV/AIDS (acquired immune deficient syndrome), a human infectious disease was once listed as the No. 1 disease killer in US (1993). After the invention of antiviral drug cocktails-high active anti-retroviral therapy (HAART), most HIV-infected patients can survive much longer than with single antiviral drugs or vaccines alone. However, it turns out to be a chronic disease owing to being incapable to eradicate HIV from infectious patients. Furthermore, potential newly outbreak of HIV epidemics caused by widespread drug-resistance or viral mutations is still looming over the globe. In order to counteract these drawbacks and possibilities of HAART, many hurdles must be passed. More creative and revolutionary ideas and worldwide cooperation efforts among academics, drug developers and governmental funding bodies must be encouraged and promoted. In this perspective, many important drawbacks and weaknesses relating to HIV/AIDS therapies are outlined and possible future solutions are highlighted.

Genetic and bioinformatic studies of antidepressant drug therapeutic efficacy and toxicity: a current overview.

Antidepressants can relief human depression and reduce human depressive symptoms. Nevertheless, some undesired clinical events, such as suicide have been emerging. As for 2004, the US and European regulatory agencies began implementing verification programs to assess the influence on suicidal behavior from the use of antidepressants such as selective serotonin reuptake inhibitors (SSRIs). With the increasing number of reported cases, several newly developed antidepressants were faced with withdrawal from the markets. Despite unclear cause of suicide, researches focusing on revealing the relationship between efficacy and toxicities of antidepressants have been initiated in China and US. To deal with these undesired clinical consequences, new initiatives and revolutionary ideas have been proposed and verified. Hopefully, therapeutic efficacies and outcomes by different types of antidepressant treatments can be improved for clinical trials in future.